Phagenesis Closes Second Round
Manchester-based life sciences company Phagenesis has closed a 7 million Euro (US$9.23 million) second round of funding to accelerate its commercialisation strategy. Phagenesis Ltd, is a specialist in the treatment of dysphagia (the inability to swallow safely). The investment is led by Inventages, a life science fund specialised in treatment solutions for chronic diseases. Existing shareholders also participated in the round.
4 October 2011•2 mins read
